Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Thoracic 2Dermatologic 2Breast 2Plasma cell 1NET 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Ovarian Neoplasms 675Breast Neoplasms 265Uterine Cervical Neoplasms 240Carcinoma, Non-Small-Cell Lung 218Endometrial Neoplasms 201Fallopian Tube Neoplasms 187Carcinoma, Ovarian Epithelial 175Colorectal Neoplasms 164Stomach Neoplasms 152Pancreatic Neoplasms 144Neoplasms 143Melanoma 118Lung Neoplasms 112Carcinoma, Renal Cell 111Triple Negative Breast Neoplasms 108Prostatic Neoplasms 108Squamous Cell Carcinoma of Head and Neck 98Neoplasm Metastasis 96Esophageal Neoplasms 90Urinary Bladder Neoplasms 85Head and Neck Neoplasms 83Sarcoma 69Small Cell Lung Carcinoma 64Carcinoma, Hepatocellular 64Colonic Neoplasms 56Carcinoma, Transitional Cell 49Kidney Neoplasms 41Testicular Neoplasms 38Peritoneal Neoplasms 37Anus Neoplasms 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Diseases × Gynecologic × Clear all
NCT02837991 2020-06-04

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Celldex Therapeutics

Phase 1 Terminated
16 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡